Final results of an EORTC-GU cancers group randomized study of maintenance bacillus calmette-guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: One-third dose versus full dose and 1 year versus 3 years of maintenance

European Urology

Volumn 63, Issue 3, 2013, Pages 462-472

  Oddens, Jorg ^a   Brausi, Maurizio ^b   Sylvester, Richard ^c   Bono, Aldo ^d   Van De Beek, Cees ^e   Van Andel, George ^f   Gontero, Paolo ^g   Hoeltl, Wolfgang ^h   Turkeri, Levent ⁱ   Marreaud, Sandrine ^c   Collette, Sandra ^c   Oosterlinck, Willem ^j  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

^b B Ramazzini Hospital   (Italy)

^c EORTC DATA CENTER   (Belgium)

^d OSPEDALE DI CIRCOLO   (Italy)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^g MOLINETTE HOSPITAL   (Italy)

^h Kaiser Franz Josef Spital ^*  (Austria)

ⁱ MARMARA UNIVERSITY   (Turkey)

^j GHENT UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

Adjuvant treatment; Bacillus Calmette Guerin; Immunotherapy; Maintenance therapy; Non muscle invasive bladder cancer; Randomized Controlled Trial; Urinary bladder

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER PATIENT; CHEMICAL CYSTITIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FEVER; FEMALE; FOLLOW UP; HEMATURIA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MALE; PRIORITY JOURNAL; TRANSURETHRAL RESECTION;

ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA, PAPILLARY; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PATIENT DROPOUTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84872961570     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.10.039     Document Type: Article

References (18)

1. R.J. Sylvester, A.P.M. van der Meijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466 477
2. M. Brausi, J.A. Witjes, and D. Lamm A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group J Urol 186 2011 2158 2167
3. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
4. R.J. Sylvester, M.A. Brausi, and W.J. Kirkels Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder Eur Urol 57 2010 766 773
5. P.U. Malmstrom, R.J. Sylvester, and D.E. Crawford An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer Eur Urol 56 2009 247 256
6. A. Morales, D. Eidinger, and A.W. Bruce Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors J Urol 116 1976 180 183
7. S. Hinotsu, H. Akaza, and S. Naito Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer BJU Int 108 2011 187 195
8. L.R. Kavoussi, R.J. Torrence, and D.P. Gillen Results of 6 weekly intravesical bacillus Calmette-Guérin instillations on the treatment of superficial bladder tumors J Urol 139 1988 935 940
9. D.L. Lamm, B.A. Blumenstein, and J.D. Crissman Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study J Urol 163 2000 1124 1129 (Pubitemid 30169376)
10. A.P. van der Meijden, M. Brausi, V. Zambon, W. Kirkels, C. de Balincourt, and R. Sylvester Intravesical instillation of epirubicin, bacillus Calmette-Guérin and bacillus Calmette-Guérin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial J Urol 166 2001 476 481 (Pubitemid 32652226)
11. M. Colombel, F. Saint, D. Chopin, B. Malavaud, L. Nicolas, and P. Rischmann The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study J Urol 176 2006 935 939 (Pubitemid 44142611)
12. J.A. Martinez-Pineiro, N. Flores, and S. Isorna Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer BJU Int 89 2002 671 680 (Pubitemid 34429530)
13. J.A. Martinez-Pineiro, L. Martinez-Pineiro, and E. Solsona Has a 3-fold decreased dose of bacillus Calmette-Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial J Urol 174 2005 1242 1247 (Pubitemid 41318691)
14. A. Ojea, J.L. Nogueira, and E. Solsona A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guérin (27 mg) versus very low-dose bacillus Calmette-Guérin (13.5 mg) versus mitomycin C Eur Urol 52 2007 1398 1406 (Pubitemid 47449726)
15. B.A. Inman Re: Has a 3-fold decreased dose of bacillus Calmette-Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial J Urol 175 2006 1960 author reply 1960-1
16. M. Brausi, L. Collette, and K. Kurth Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies Eur Urol 41 2002 523 531
17. M.O. Grimm, C. Steinhoff, X. Simon, P. Spiegelhalder, R. Ackermann, and T.A. Vogeli Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study J Urol 170 2003 433 437 (Pubitemid 36870218)
18. H.E. Schwaibold, S. Sivalingam, F. May, and R. Hartung The value of a second transurethral resection for T1 bladder cancer BJU Int 97 2006 1199 1201 (Pubitemid 43907321)